Adenocarcinoma
Conditions
Keywords
Adenocarcinoma, Pancreatic cancer, Adiponectin, Blood sample
Brief summary
This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (\<2cm), the chances of recovery are very good. But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. Today, there is no any effective means of detection... Blood markers can be a simple means of early detection
Detailed description
The purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.
Interventions
BIOLOGICALBlood sample
Blood sample will be performed
Sponsors
Centre Hospitalier Universitaire de Saint Etienne
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
ADENOCARCINOMA GROUP Inclusion Criteria: * Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis. * At the start of treatment (before surgery / 1st course of chemotherapy) * Age ≥ 18 years * Patient affiliated or entitled to a social security system
Exclusion criteria
* Patient refusal * Acute renal failure * Child-Pugh B or C cirrhosis * Patient under guardianship or curators * Other synchronous cancer or history of cancer \<5 years * Language barrier CONTROL GROUP Inclusion Criteria: * Age ≥ 40 years * Patient affiliated or entitled to a social security system * Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum adiponectin concentration | Months : 0 | Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum CA19.9 concentration | Months : 0, 3, 6, 9, 12 | Measure by blood sample result Threshold for Comparison of diagnostic performance compared to serum adiponectin concentration |
| Tumor response and progression rates according to RECIST v1.1 | Month 12 | Tumor response and progression rates defined according to RECIST v1.1 criteria according to a serum threshold of the prognostic biomarker to be identified by logistic regression analyzes. |
| Progression-free survival | Months : 24 | — |
| Overall survival | Months : 24 | — |
| Serum adiponectin concentration | Months : 3, 6, 9, 12 | Measure by blood sample result Serum adiponectin concentration to correlate with cancer progression or not. |
Countries
France
Contacts
Primary ContactNicolas WILLIET, MD
Backup ContactJean-Marc PHELIP, MD-PhD
Outcome results
None listed